Browsing Tag

Nasdaq:ADGI

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects…

Eli Pacheco Sep 12, 2022 0

Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and…

Health

Adagio Therapeutics to Participate in Upcoming Investor Conferences

Eli Pacheco Sep 7, 2022 0

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and…

Health

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

Eli Pacheco Apr 14, 2022 0

WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and…

Health

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Eli Pacheco Feb 22, 2022 0

Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of…

Health